Analyst at JP Morgan Cazenove Reiterates The Smith Nephew PLC (LON:SN) Overweight Rating They’ve Had

April 26, 2018 - By Clifton Ray

Smith & Nephew plc (LON:SN) Logo

Investors sentiment decreased to 0.98 in Q4 2017. Its down 0.16, from 1.14 in 2017Q3. It fall, as 20 investors sold Smith & Nephew plc shares while 34 reduced holdings. 18 funds opened positions while 35 raised stakes. 45.63 million shares or 5.04% less from 48.05 million shares in 2017Q3 were reported.

Baker Avenue Asset Mgmt L P reported 218,981 shares. Bancshares Of Montreal Can reported 149,327 shares. Blackrock Inc, New York-based fund reported 3.87 million shares. Parkwood Lc invested 0.08% of its portfolio in Smith & Nephew plc (LON:SN). Manufacturers Life Ins Co The invested in 0% or 57,127 shares. The Ohio-based Pub Employees Retirement Of Ohio has invested 0.01% in Smith & Nephew plc (LON:SN). Us Bancshares De holds 0% or 149 shares in its portfolio. Schwab Charles Incorporated has invested 0% in Smith & Nephew plc (LON:SN). Millennium Mgmt Ltd Limited Liability Company reported 2.98M shares. Cambridge Invest Rech holds 0% or 17,050 shares. Tudor Invest Et Al invested 0% in Smith & Nephew plc (LON:SN). Alliancebernstein Lp has 123,029 shares for 0% of their portfolio. Oz Mgmt L P has 0.01% invested in Smith & Nephew plc (LON:SN). First Manhattan owns 712 shares. Wells Fargo & Mn holds 0% or 1.71 million shares.

Since January 3, 2018, it had 0 insider purchases, and 13 insider sales for $1.02 million activity. The insider Hink Kirsten A sold $9,509. $58,481 worth of Smith & Nephew plc (LON:SN) was sold by SANCHEZ ANTONIO R JR on Thursday, March 1. Thill Howard J SR sold 8,251 shares worth $24,596. Sanchez Patricio D. had sold 13,202 shares worth $49,059 on Monday, April 16. 7,960 Smith & Nephew plc (LON:SN) shares with value of $44,664 were sold by Kopel Gregory B.

Smith Nephew PLC (LON:SN) Rating Reaffirmed

JP Morgan Cazenove reiterated their Overweight rating on Smith Nephew PLC (LON:SN) shards via analysts note issued on Wednesday, 25 April.

Investors sentiment decreased to 0.98 in Q4 2017. Its down 0.16, from 1.14 in 2017Q3. It fall, as 20 investors sold Smith & Nephew plc shares while 34 reduced holdings. 18 funds opened positions while 35 raised stakes. 45.63 million shares or 5.04% less from 48.05 million shares in 2017Q3 were reported.

Baker Avenue Asset Mgmt L P reported 218,981 shares. Bancshares Of Montreal Can reported 149,327 shares. Blackrock Inc, New York-based fund reported 3.87 million shares. Parkwood Lc invested 0.08% of its portfolio in Smith & Nephew plc (LON:SN). Manufacturers Life Ins Co The invested in 0% or 57,127 shares. The Ohio-based Pub Employees Retirement Of Ohio has invested 0.01% in Smith & Nephew plc (LON:SN). Us Bancshares De holds 0% or 149 shares in its portfolio. Schwab Charles Incorporated has invested 0% in Smith & Nephew plc (LON:SN). Millennium Mgmt Ltd Limited Liability Company reported 2.98M shares. Cambridge Invest Rech holds 0% or 17,050 shares. Tudor Invest Et Al invested 0% in Smith & Nephew plc (LON:SN). Alliancebernstein Lp has 123,029 shares for 0% of their portfolio. Oz Mgmt L P has 0.01% invested in Smith & Nephew plc (LON:SN). First Manhattan owns 712 shares. Wells Fargo & Mn holds 0% or 1.71 million shares.

Since January 3, 2018, it had 0 insider purchases, and 13 insider sales for $1.02 million activity. The insider Hink Kirsten A sold $9,509. $58,481 worth of Smith & Nephew plc (LON:SN) was sold by SANCHEZ ANTONIO R JR on Thursday, March 1. Thill Howard J SR sold 8,251 shares worth $24,596. Sanchez Patricio D. had sold 13,202 shares worth $49,059 on Monday, April 16. 7,960 Smith & Nephew plc (LON:SN) shares with value of $44,664 were sold by Kopel Gregory B.

Smith & Nephew plc (LON:SN) Ratings Coverage

Among 7 analysts covering Smith & Nephew (LON:SN), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Smith & Nephew has GBX 1530 highest and GBX 1290 lowest target. GBX 1414.93’s average target is 3.66% above currents GBX 1365 stock price. Smith & Nephew had 13 analyst reports since November 3, 2017 according to SRatingsIntel. Morgan Stanley maintained the shares of SN in report on Tuesday, February 13 with “Equal Weight” rating. The rating was upgraded by JP Morgan on Thursday, January 25 to “Overweight”. The rating was maintained by Jefferies on Monday, November 6 with “Buy”. The company was maintained on Thursday, April 5 by JP Morgan. The firm has “Buy” rating given on Thursday, April 12 by Jefferies. On Monday, November 6 the stock rating was maintained by JP Morgan with “Neutral”. Deutsche Bank maintained the shares of SN in report on Tuesday, April 17 with “Hold” rating. The stock of Smith & Nephew plc (LON:SN) has “Overweight” rating given on Thursday, February 1 by JP Morgan. HSBC upgraded the shares of SN in report on Monday, March 26 to “Buy” rating. The rating was maintained by JP Morgan with “Overweight” on Wednesday, February 7.

The stock decreased 0.91% or GBX 12.5 during the last trading session, reaching GBX 1365. About 1.96M shares traded. Smith & Nephew plc (LON:SN) has 0.00% since April 26, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Smith & Nephew plc (LON:SN) to report earnings on May, 8. They expect $0.21 EPS, up 120.00 % or $1.26 from last year’s $-1.05 per share. SN’s profit will be $1.83 million for 1625.00 P/E if the $0.21 EPS becomes a reality. After $0.28 actual EPS reported by Smith & Nephew plc for the previous quarter, Wall Street now forecasts -25.00 % negative EPS growth.

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company has market cap of 11.92 billion GBP. The firm offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints; and arthroscopic enabling technologies for healthcare providers, such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue. It has a 15.56 P/E ratio. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery services and products; knee implant products for specialized knee replacement procedures; and hip implant products for reconstruction of the hip joint, as well as various products and technologies to assist in surgical treatment of the ear, nose, and throat.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: